Immunic (IMUX) Expected to Release Earnings on Thursday

Immunic (NASDAQ:IMUX) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Immunic to announce earnings of ($1.1756) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.37). On average, analysts expect Immunic to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Immunic Stock Performance

Shares of IMUX stock opened at $13.05 on Thursday. The company has a market capitalization of $177.74 million, a price-to-earnings ratio of -2.34 and a beta of 1.37. Immunic has a one year low of $5.06 and a one year high of $15.84. The company’s 50-day moving average is $14.24 and its 200 day moving average is $11.41.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on IMUX shares. Stifel Nicolaus set a $25.00 price objective on shares of Immunic and gave the stock a “buy” rating in a report on Thursday, April 16th. Wall Street Zen downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Sunday, April 19th. D. Boral Capital lowered Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research note on Friday, May 29th. Finally, Wolfe Research assumed coverage on Immunic in a report on Friday, May 22nd. They set an “outperform” rating on the stock. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunic currently has a consensus rating of “Buy” and an average target price of $47.57.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Qube Research & Technologies Ltd bought a new position in Immunic during the third quarter valued at approximately $29,000. Two Sigma Investments LP bought a new stake in Immunic in the 3rd quarter worth approximately $52,000. Virtu Financial LLC bought a new stake in Immunic in the 3rd quarter worth approximately $99,000. XTX Topco Ltd purchased a new stake in Immunic during the 4th quarter valued at $120,000. Finally, Jane Street Group LLC raised its stake in Immunic by 46.8% during the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock valued at $153,000 after buying an additional 91,346 shares during the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.